Articles tagged with Molecular Imaging
The SNMMI 2026 Annual Meeting will showcase the latest scientific developments driving advances in nuclear medicine, including earlier diagnosis, personalized treatment, and improved disease management for various conditions. The meeting will feature over 150 scientific sessions, satellite symposia, and a cutting-edge exhibit hall.
A new PET biomarker outperforms established risk scores in predicting survival for large B-cell lymphoma patients. Metabolic tumor volume, derived from PET imaging, was found to be an important predictor of progression-free survival.
Salk scientists and collaborators advance visualization technology using visible-spectrum antigen-stabilizable fluorescent nanobodies (VIS-Fbs), reducing background fluorescence by up to a hundredfold. The new probe enables high spatial and temporal precision, allowing for real-time tracking of dynamic changes in living models.
Researchers developed a new chelator to improve cancer imaging and therapy. Additionally, analyzing brain glucose uptake in patients with non–small cell lung cancer may help predict prognosis. A targeted PET imaging agent is also being developed to detect liver cancer more effectively.
A new optical-coupled scanning probe microscope uses a remote liquefaction cryogen-free system to visualize individual atoms and probe electronic and chemical properties without freezing budget. The system achieves stable base temperature and low noise levels, making it ideal for continuous experiments and studies of slow processes.
Researchers have developed new PET tracers that can track synaptic density in epilepsy and monitor tau buildup in Alzheimer's disease. A novel PET tracer also maps cellular energy use across the body, enabling faster imaging approaches for studying mitochondrial function.
Recent studies published in The Journal of Nuclear Medicine have made significant advancements in the field. Researchers have developed a new tracer to detect active collagen turnover following myocardial infarction and evaluated folate-based radioconjugates for ovarian cancer imaging. Additionally, targeted radiotherapy shows promise ...
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Kiran Solingapuram Sai's research aims to detect microtubule dysfunction early in Alzheimer's disease using a first-in-class PET radiotracer. The study will establish a reproducible imaging framework for this target.
Researchers Ansel Hillmer and Eric Webb have received the $100,000 Drs. Jane & Abass Alavi Mars Shot Research Award to advance imaging research in infection and inflammation for Alzheimer's disease. They aim to develop a PET radiotracer targeting CSF1R to diagnose and monitor brain inflammation.
Dr. Carolyn J. Anderson has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop a PET radiotracer for imaging vaso-occlusive crisis in sickle cell disease. The award will support the production and validation of an easy-to-produce and high-yielding PET radiotracer, 18F-LLP2A, for rapid translation to patients.
The study investigated the link between heart attack-induced inflammation and cognitive decline, as well as the potential of PET-based metabolic tumor volume to predict CAR T-cell therapy outcomes. Additionally, researchers combined advanced imaging with genetic profiling to explore hidden metabolic patterns in recurrent brain cancer.
Researchers Haj-Mirzaian and Heidari aim to develop non-invasive imaging biomarker <sup> 18 </sup> F-NaF PET/CT for early calciphylaxis diagnosis in dialysis-dependent patients. This could lead to timely interventions, reduced mortality, and improved patient outcomes.
Dr. Chun Li has been awarded the SNMMI Mars Shot Research Fund Award to investigate the PET radiotracer 64Cu-DbCD11b for detecting vulnerable atherosclerotic plaques. The study aims to assess the non-invasive assessment of vulnerable plaques and aid in patient risk identification and treatment.
Dr. David H. Ballard, MD, has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop novel PET/MR imaging techniques for metabolic activity and inflammation in Crohn's disease. The study aims to improve biologically informed decision-making and guide treatment decisions.
Researchers have developed new imaging techniques to detect hidden infections, inflammatory diseases, and cancers, while also evaluating the effectiveness of AI-powered tumor measurement and targeted radiotherapy for advanced solid tumors.
A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients as little as four weeks after treatment initiation. The imaging technique uses macrophages, a type of white blood cell, as a biomarker for disease activity, potentially allowing non-responders to pursue more effective therapies.
Researchers have developed a new PSMA-targeted PET tracer that shows promise in early human studies, providing strong tumor uptake and favorable radiation dosimetry. Additionally, advanced dynamic PET imaging has been used to track heart amyloid buildup more precisely, detecting significant reductions after six months of tafamidis ther...
A novel quantitative imaging approach using PET and MRI can identify limbic-predominant age-related TDP-43 encephalopathy (LATE), a distinct neurodegenerative disorder resembling Alzheimer's disease. This framework may guide targeted diagnostic work-up and personalized care for dementia patients.
Researchers have made significant advancements in nuclear medicine by developing a new reporting framework for PET/CT scans, using targeted radiation therapy to treat sarcoma, and investigating how genetic mutations affect prostate cancer treatment outcomes. These studies aim to improve diagnosis and treatment for various cancers.
Scientists have created a way to hear a single molecule 'sing' using infrared-integrated STM. This technique combines infrared excitation with scanning tunneling microscopy, allowing for the detection of individual molecular vibrations.
Researchers are testing new targeted radiation approaches for early colorectal cancer, HER2-positive breast cancer, and advanced prostate cancer. Imaging tools track treatment movement and help evaluate dosing and safety.
Ken Herrmann will lead the journal for five years, focusing on global engagement and impact. He succeeds Johannes Czernin, who guided JNM through significant growth and expansion.
The University of Missouri has launched its first human clinical trial using Eye90 microspheres, a radiopharmaceutical breakthrough device manufactured on campus. The study aims to assess the safety and effectiveness of Eye90 in treating unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer.
Researchers used advanced PET imaging techniques to study the effects of traumatic spinal cord injuries on nerve cells. Additionally, whole-body PET scans were used to map brain-body immune cross-talk during immune responses.
Researchers have developed new CXCR4-targeting radiolabeled peptides for cancer imaging and therapy, producing clear tumor images and extending survival in preclinical testing studies. Additionally, PET scans are being used to predict prostate cancer outcomes, identify primary aldosteronism, and guide treatment decisions.
Researchers developed a novel combined PET imaging approach to personalize radiotherapy for head and neck cancers, creating biologic maps that show tumor characteristics. This strategy led to greater than 90% predicted tumor control probability, outperforming previous literature.
Scientists have developed a new technique that combines rotational ultrasound tomography (RUST) with photoacoustic tomography (PAT) to create 3D color images of soft tissues and blood vessel function. This method has the potential to enhance breast tumor imaging, monitor nerve damage caused by diabetes, and brain imaging.
This study introduces a new FAP-targeting peptide that shows strong tumor uptake and effective tumor growth inhibition when paired with lutetium-177. Additionally, researchers have identified distinct metabolic and structural brain patterns that differentiate probable LATE, Alzheimer disease, and their frequent overlap.
Recent studies published in The Journal of Nuclear Medicine explore the use of interim PET scans to predict treatment response and survival in patients with large B-cell lymphoma. Additionally, a phase 2 trial evaluates the safety and effectiveness of a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in advanced...
A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, completely eradicating tumors in preclinical models. Claudin-18.2-based theranostics could meaningfully change patient care by enabling non-invasive tumor identification and targeted radiation therapy.
Researchers at IIT develop optical microscopy technique that combines polarization and dark-field microscopy to observe cells with high contrast, preserving their natural conditions. The next step involves using AI to enrich images with molecular information related to diseases.
Researchers developed new imaging approaches using specialized amino acid PET tracers to visualize aggressive breast, lung, and glioma cancers. The studies showed promising results, highlighting the potential of these tools for future cancer imaging and guiding targeted therapies.
Researchers have developed new PET imaging tracers to detect and treat colorectal, thyroid, and lymphoma cancers. The tracers enable targeted radiation delivery, personalized dosing, and improved detection of inflammation in large blood vessels and liver lesions.
A team of MIT engineers developed a deep-learning model that predicts how individual cells will fold, divide, and rearrange during a fruit fly's earliest stage of growth. The model achieved 90% accuracy in predicting the movement of 5,000 cells over the first hour of development.
Recent studies explored novel biomarkers for kidney cancer spread detection, heart scans for ATTR amyloidosis diagnosis, and radiation therapy delivery for neuroendocrine tumors. Additionally, researchers developed a new PET tracer to track heart-healing cells after a heart attack.
Researchers developed multimodal models integrating imaging, clinical, and molecular data from TAILORx tissue biorepository for early-stage breast cancer. The models demonstrated enhanced prognostic performance compared to existing methods, highlighting their potential for personalized treatment decision-making.
This supplement highlights key areas of focus for theranostics, including clinical lessons, education, science, multidisciplinary collaboration, and equity. It also explores new frontiers beyond oncology and examines finance, sustainability, policy, strategy, and future directions.
Recent studies explore new PET/CT imaging methods for prostate cancer staging and detection. Researchers assess improved performance of these advanced scans in detecting lymph node or bone spread, as well as their impact on treatment plans. Additionally, researchers examine the effectiveness of peptide receptor radionuclide therapy (PR...
Several studies examine imaging tools for detecting prostate cancer, testing new PET tracers for spotting aggressive tumors. Researchers also explored a new scan to detect gastrointestinal stromal tumors and improved imaging agents for pancreatic cancer diagnosis.
Researchers have made significant advancements in detecting and treating prostate cancer and ALS using innovative imaging techniques. A new PET tracer has been developed to track Huntington disease protein aggregates, offering a potential noninvasive monitoring tool. Additionally, studies have compared two types of PET scans for spotti...
The Society of Nuclear Medicine and Molecular Imaging emphasizes the importance of education, training, and experience for safe and effective delivery of radiopharmaceutical therapy. Specialized expertise is needed to handle radioactive compounds and ensure patient safety.
A new radioimmunotherapy approach has been developed to treat HER2-positive breast cancer, resulting in complete and histologic cures with minimal toxicities. The treatment uses a pretargeted approach to directly target tumors, reducing the risk of radiation toxicity to healthy tissues.
Researchers developed a detailed kidney model to study radiation distribution, highlighting uneven exposure across different nephron types. Tumor volume changes and PSMA PET imaging also showed promise for predicting outcomes in prostate cancer patients. New targeted therapies and imaging strategies aim to improve diagnosis and treatment.
Researchers at the University of Queensland have captured high-resolution images of the yellow fever virus, shedding light on its structural differences between the vaccine strain and disease-causing variants. The study reveals that these differences impact how the immune system recognizes the virus.
Researchers from The University of Osaka and The University of Tokyo have developed a novel technology that visualizes specific molecules inside living cells using light. The new photo-responsive alkyne tag enables precise visualization without disrupting molecular dynamics.
Researchers have developed a new PET imaging agent that can distinguish true tumor response from inflammation during immune checkpoint inhibitor therapy. This breakthrough has the potential to improve early treatment assessment and patient outcomes.
A new approach to PET imaging can identify patients at risk of poor functional recovery after a heart attack by visualizing CXCR4, a cellular protein involved in inflammation. This technique enables timely implementation of treatments to mitigate inflammation and prevent heart failure progression.
Recent studies published in The Journal of Nuclear Medicine explore the use of artificial intelligence to improve PSMA PET/CT scan interpretation, as well as its impact on treatment decisions for patients with recurrent prostate cancer. Brain metabolic changes and fibroblast activation protein (FAP) PET imaging also reveal new insights...
The new Molecular Imaging and Theranostics Centre at NUH and NUS Medicine enables faster, safer and more precise diagnoses, while researchers can observe real-time tracer movement throughout the body. This opens possibilities for validating next-generation diagnostics and therapies, advancing theranostics.
Researchers developed a high-speed whole-body SPECT method to track tumor evolution and personalize prostate cancer treatment. The new approach enabled faster monitoring, allowing for earlier adjustments to treatment plans and improved patient outcomes.
Studies have found that men with advanced prostate cancer can benefit from continuing PSMA therapy despite early PSA rise, while a new PET/CT scan may improve surgery decisions in pancreatic cancer. Molecular imaging advancements also hold promise for distinguishing aggressive kidney cancers and guiding treatment decisions.
Recent studies published in The Journal of Nuclear Medicine have made significant breakthroughs in prostate cancer treatment, with multiple therapies showing promise. Researchers have also discovered ways to reduce radiation exposure in PET scans and tracked the effects of alpha therapy on patients.
Researchers from UCL and Imperial College London have discovered how life-saving antibiotics called polymyxins target the outer layer of Gram-negative bacteria. By triggering the production and shedding of this armor, polymyxins create gaps in the cell's defenses, allowing the antibiotic to enter and kill the bacteria.
Researchers have developed promising therapies for advanced prostate cancer, improved brain imaging capabilities, and enhanced liver cancer detection. A new alpha therapy shows promise in treating thyroid cancer, while AI-assisted tracking systems enhance prognosis prediction in prostate cancer imaging.
A new study found that combining molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) increases invasive cancer detection while moderately increasing recall rates. MBI detected an additional 6.7 cancers per 1,000 screenings in women with dense breasts.
A new PET tracer, 64Cu-NOTA-EV-F(ab′2), has been developed for same-day imaging of triple-negative breast and urothelial bladder cancers. The tracer exhibits rapid tumor accumulation and high specificity in nectin-4 positive tumors, enabling accurate non-invasive visualization of this protein.
Faster PET scans show promise for detecting liver inflammation and metabolic dysfunction-associated steatohepatitis. An AI tool combines multiple PET scans to integrate data from different tracers, improving disease insights. New imaging techniques enhance breast cancer surgery and predict recovery after heart attack.
A new targeted radiation approach has achieved a near-complete response in three patients with solitary fibrous tumor (SFT), a rare and aggressive form of cancer. The therapy significantly reduced cancer activity and provided symptom relief, highlighting its potential as a treatment option.
New PET imaging agents show promise for detecting thyroid and neuroendocrine tumors, as well as reversing fibrosis in the heart. Researchers also explored tau PET scans for Alzheimer's detection and SSTR PET/CT for meningioma diagnosis. These advancements hold potential for improving cancer treatment and patient outcomes.